LIV Emles at Home ETF

Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today, it is devoting a substantial amount of its recent $40 million dollar financing to research and development (R&D). According to BioCentury, Strategy-The Inside Story, "There is really only one thing that sustainable companies must do: make sure the pipeline is full of products that will come on the market at reasonable intervals and provide reasonable levels of revenue. Given the reality of pharmaceutical failure rates, the characteristics of successful business builders are thus fairly straightforward: they spend enough on R&D and do enough partnering and acquisitions to keep the compounds flowing." Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals, stated, "Although it is not in our strategy to partner yet, we feel particularly exuberant about the strength of our pipeline to keep the compounds flowing and its possibilities for success. Not only that, we are purposely positioning each one of our promising drugs now to be continuous revenue streams, even before our initial HIV drug SP-01A hopefully comes on the market." Samaritan Pharmaceuticals: "We LIV....to Save Lives." Samaritan Pharmaceuticals is a drug development company driven to discover, develop, and commercialize, innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease. Samaritan, in collaboration with Georgetown University, is advancing eight promising compounds, out of its rich pipeline of 250 possible drug candidates, all of which have the potential to create revenue-generating opportunities. Additional information is at www.samaritanpharma.com. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.